C4 Therapeutics (CCCC) Other Operating Expenses (2024 - 2025)

C4 Therapeutics' (CCCC) quarterly Other Operating Expenses came in at $10.7 million in Q3 2025, up 340.42% quarter-over-quarter from $2.4 million in Q1 2024.

C4 Therapeutics (CCCC) Other Operating Expenses (2024 - 2025) Analysis & Trends

C4 Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at $10.7 million for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $10.7 million in Q3 2025; TTM through Mar 2026 was $10.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.7 million, changed N/A from the prior year.
  • Other Operating Expenses rose to $10.7 million in Q3 2025 per CCCC's latest filing, from $2.4 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $10.7 million in Q3 2025 and bottomed at $2.4 million in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 C4 Therapeutics 460.17 Mn 224.50 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 10.73 Mn
Mar 31, 2024 2.44 Mn